Xeris Pharmaceuticals

Xeris Pharmaceuticals is a specialty pharmaceutical company that leverages novel formulation technology platforms to develop and commercialise ready-to-use liquid-stable injectables. The company is focused on creating medicines that are easier to use, including its Gvoke^® glucagon injection.

Headquarters
Xeris Pharmaceuticals, Inc
180 North LaSalle Street
Suite 1600
Chicago
IL 60601
United States

Phone / Contact

T: +1 844 445 5704

Connect

Xeris Pharmaceuticals is a specialty pharmaceutical company that leverages novel formulation technology platforms to develop and commercialise ready-to-use liquid-stable injectables. The company is focused on creating medicines that are easier to use, including its Gvoke® glucagon injection, which uses Xeris’s technology to deliver ready-to-use solutions for patients and caregivers alike.

Xeris was founded in 2005 and its shares are traded on the NASDAQ Global Select index (NASDAQ GS: XERS).

Articles by Xeris Pharmaceuticals

Dr Steven Prestrelski

XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS

Steven Prestrelski introduces the XeriJect non-aqueous formulation technology that creates formulations with visco-elastic properties, opening the door to subcutaneous injection of difficult-to-formulate biologics, such as monoclonal antibodies, at very high concentrations.

ENABLING A NEW PARADIGM FOR PEPTIDE DRUG DEVELOPMENT

Michael Neely reviews peptide formulations and introduces Xeris's XeriSol™ technology and its potential paradigm-changing capabilities.

A VIEW ON THE USE OF APROTIC SOLVENTS IN PARENTERAL DRUG FORMULATIONS

Michael Neely presents a review and discussion of the status of aprotic solvents as a solubilising vehicle for parenteral drug formulations in the context of the industry’s increasing interest in biologic drugs.

Top